Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

QIAGEN N.V. today announced that the U.S. Food and Drug Administration (FDA) has granted two 510(k) clearances for its real-time PCR (polymerase chain reaction) instrument Rotor-Gene Q MDx and a compatible test for the detection of Influenza A/B, the artus Infl A/B RG RT-PCR Kit, for in vitro diagnostic use.

From QIAGEN Manchester Limited 17 Apr 2012

Morphotek commences MORAb-004 Phase II study in metastatic colorectal cancer

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 in the treatment of metastatic colorectal cancer that is refractory to all standard therapy.

17 Apr 2012

Consumption of long-chain omega-3 PUFAs lowers risk of colorectal polyps in women

New research finds that omega-3 polyunsaturated fatty acids (PUFAs) found in seafood (long-chain omega-3s) may reduce the risk of precancerous colorectal polyps in women, enhance the muscular benefits of strength training in older women and improve eye health after corneal surgery.

12 Apr 2012

Experts share top 5 springtime fruits and vegetables that fight cancer

The price of springtime fruits and vegetables seems to increase each year. But when buyers break this expense down to cents, they realize stocking up on these cancer-fighting foods still makes economical sense, say experts from The University of Texas MD Anderson Cancer Center.

12 Apr 2012

Research explores power of offering colon cancer screening options

Researchers find that when given a choice of methods, more people will opt to get screened for colon cancer. Meanwhile, a separate study found that insurance coverage of lung cancer screenings for high-risk patients could prevent -- at a low cost -- thousands of deaths annually.

12 Apr 2012

Lung cancer screening could be cost effective: Study finds

A new study shows that screening longtime tobacco users for lung cancer would be less costly than the widely accepted practice of screening for breast, cervical and colorectal cancers and would reduce the death toll of lung cancer by an estimated 15,000 lives a year.

11 Apr 2012

Majority of Michigan oncology practices follow treatment guidelines for common cancers

A majority of Michigan oncology practices participating in a statewide consortium followed treatment guidelines for common cancers, but had gaps in managing symptoms and end-of-life care, according to a new study.

11 Apr 2012

High cancer treatment costs in the US – are they worth it? Study explores

Healthcare in the United States is costlier than care in other countries. A new analysis suggests that the cost may be worth it at least when it comes to cancer care. Americans may pay more for cancer treatment, but they also live longer after diagnosis — getting a benefit that offsets their higher health expenses the study says.

10 Apr 2012

Potential role of aspirin in reducing risk of cancer death

A new report by American Cancer Society scientists says new data showing aspirin's potential role in reducing the risk of cancer death bring us considerably closer to the time when cancer prevention can be included in clinical guidelines for the use of aspirin in preventative care.

10 Apr 2012

DDW to be held May 19-22 in San Diego

Thousands of physicians, researchers and academics from around the world will gather in San Diego in May for Digestive Disease Week- (DDW), the premiere scientific conference in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

6 Apr 2012

Regeneron, Sanofi announce clinical and regulatory update for ZALTRAP

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the Biologics License Application (BLA) for the investigational agent ZALTRAP (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen.

6 Apr 2012

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that patient access to premium-priced targeted cancer treatments in Brazil and Mexico is improving, creating an opportunity for developers and marketers of epidermal growth factor receptor (EGFR) inhibitors.

5 Apr 2012

ARI-4175 drug may treat colorectal cancer patients with KRAS mutation

When combined with other treatments, the drug cetuximab-which works by slowing or stopping the growth of cancer cells-has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers. Unfortunately, about 40 percent of colorectal cancer patients-specifically those who carry a mutated form of a gene called KRAS-do not respond to the drug. Researchers at Fox Chase Cancer Center in Philadelphia, however, have been working on a way to overcome this resistance to cetuximab by unleashing a second cetuximab driven mechanism using a novel drug called ARI-4175.

5 Apr 2012

Multimarker molecular stool test for colon cancer unaffected by medication, lifestyle factors

Research on an investigational DNA methylation test for colorectal cancer demonstrated that the only clinical variable that influenced test results was age, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

4 Apr 2012

Researchers discover two optimal gene targets for new colorectal cancer test

A study presented today by Mayo Clinic researchers at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago identified two genes that are optimal targets to be analyzed in a new noninvasive test for colorectal cancer developed by Mayo Clinic, in collaboration with Exact Sciences Corporation.

4 Apr 2012

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Keryx Biopharmaceuticals, Inc. reported today that the Phase 3 "X-PECT" clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

3 Apr 2012

$Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint$

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Aeterna Zentaris Inc. today announced that the Phase 3 "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

2 Apr 2012

UH clinical trial to evaluate stool DNA testing for colon cancer

In a first-of-its-kind clinical trial, physician-scientists at University Hospitals (UH) Case Medical Center's Seidman Cancer Center and Case Western Reserve University School of Medicine are studying a promising new non-invasive technology for colon cancer screening. The four-year study is recruiting patients to compare the effectiveness of stool DNA (SDNA) testing with colonoscopy for detecting large colon polyps.

31 Mar 2012

Researchers identify new population of intestinal stem cells

Vanderbilt-Ingram Cancer Center researchers have identified a new population of intestinal stem cells that may hold clues to the origin of colorectal cancer.

30 Mar 2012

Rates of cancer diagnoses and deaths continue to decline in the U.S.

A report from the nation's leading cancer organizations shows rates of death in the United States from all cancers for men and women continued to decline between 2004 and 2008. The findings come from the latest Annual Report to the Nation on the Status of Cancer.

29 Mar 2012